Unknown

Dataset Information

MO669FIRST RESULTS OF THE COVID-19 PATIENTS TREATED WITH THE SERAPH® 100 MICROBIND® AFFINITY FILTER (COSA) REGISTRY


ABSTRACT: Abstract

Background and Aims

The COVID-19 pandemic has serious impact on health and economics worldwide. Despite the recent advent of SARS-Cov-2 vaccines, treatment options are needed, yet pharmacologic interventions remain limited. Several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. The Seraph® 100 Microbind® Affinity adsorber (Exthera Medical, CA, USA) has recently been introduced for the elimination of several pathogens from the blood and an emergency authorization in patients with COVID-19 was granted by the FDA. Bacteria, viruses (including the SARS-CoV-2 spike glycoprotein), fungi and toxins have been shown to bind to the immobilized heparin on the ultra-high

SUBMITTER: Schmidt J 

PROVIDER: S-EPMC8194996 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature